Theravance Biopharma (TBPH) Misses Q4 EPS by 47c

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($1.64), $0.47 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $4.84 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c